Clinical characteristics of the study cohort
| Variable at diagnosis . | Value . |
|---|---|
| Age, y | |
| Median (range) | 64 (45-79) |
| Sex, n (%) | |
| Male | 14 (88) |
| Female | 2 (12) |
| Type of MM, n (%) | |
| IgA | 8 (50) |
| IgG | 8 (50) |
| κ | 8 (50) |
| Λ | 8 (50) |
| Cytogenetics at diagnosis, n (%) | |
| t(4;14) | 5 (31) |
| t(11;14) | 4 (25) |
| t(14;16) | 2 (13) |
| del13q14 | 6 (38) |
| del17p | 1 (6) |
| +9q34 | 6 (38) |
| +1q21 | 11 (69) |
| Treatment, n (%) | |
| Low-dose melphalan | 4 (25) |
| High-dose melphalan/autologous SCT | 10 (63) |
| Lenalidomide | 16 (100) |
| Bortezomib | 9 (56) |
| Dexamethasone/prednisolone | 16 (100) |
| Variable at diagnosis . | Value . |
|---|---|
| Age, y | |
| Median (range) | 64 (45-79) |
| Sex, n (%) | |
| Male | 14 (88) |
| Female | 2 (12) |
| Type of MM, n (%) | |
| IgA | 8 (50) |
| IgG | 8 (50) |
| κ | 8 (50) |
| Λ | 8 (50) |
| Cytogenetics at diagnosis, n (%) | |
| t(4;14) | 5 (31) |
| t(11;14) | 4 (25) |
| t(14;16) | 2 (13) |
| del13q14 | 6 (38) |
| del17p | 1 (6) |
| +9q34 | 6 (38) |
| +1q21 | 11 (69) |
| Treatment, n (%) | |
| Low-dose melphalan | 4 (25) |
| High-dose melphalan/autologous SCT | 10 (63) |
| Lenalidomide | 16 (100) |
| Bortezomib | 9 (56) |
| Dexamethasone/prednisolone | 16 (100) |
Ig, immunoglobulin; SCT, stem cell transplantation.